Literature DB >> 24185236

Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle.

Stefan Leucht, Stephan Heres, John M Davis.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24185236     DOI： 10.1176/appi.ajp.2013.13081129

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS.

Authors:  Bret R Rutherford; Veronika S Bailey; Franklin R Schneier; Emily Pott; Patrick J Brown; Steven P Roose
Journal:  Depress Anxiety       Date:  2015-10-05       Impact factor: 6.505

2.  Use of Placebo in Clinical Trials of Psychotropic Medication.

Authors:  Mehrul Hasnain; Abraham Rudnick; Weldon S Bonnell; Gary Remington; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2018-05       Impact factor: 4.356

3.  Placebo response in antipsychotic clinical trials: a meta-analysis.

Authors:  Bret R Rutherford; Emily Pott; Jane M Tandler; Melanie M Wall; Steven P Roose; Jeffrey A Lieberman
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

4.  Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial.

Authors:  Yoshio Hirayasu; Shin-Ichi Sato; Norifumi Shuto; Miwa Nakano; Teruhiko Higuchi
Journal:  Psychiatry Investig       Date:  2016-12-29       Impact factor: 2.505

5.  Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.

Authors:  Elan A Cohen; Howard H Hassman; Larry Ereshefsky; David P Walling; Vera M Grindell; Richard S E Keefe; Katarzyna Wyka; William P Horan
Journal:  Neuropsychopharmacology       Date:  2020-11-26       Impact factor: 7.853
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.